Nexeon MedSystems (NXNN) Upgraded at Zacks Investment Research
Zacks Investment Research upgraded shares of Nexeon MedSystems (OTCMKTS:NXNN) from a sell rating to a hold rating in a research note published on Tuesday.
According to Zacks, “Nexeon MedSystems, Inc. is a medical device company. It focused on providing innovative neurostimulation products for patients suffering from debilitating neurological diseases. Nexeon MedSystems, Inc. is based in DALLAS, United States. “
Separately, ValuEngine upgraded shares of Nexeon MedSystems from a sell rating to a hold rating in a research report on Wednesday, May 2nd.
Nexeon MedSystems (OTCMKTS:NXNN) last posted its quarterly earnings data on Monday, May 21st. The company reported ($0.03) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.03. The company had revenue of $2.87 million for the quarter, compared to analyst estimates of $1.70 million. equities research analysts predict that Nexeon MedSystems will post -0.23 EPS for the current year.
About Nexeon MedSystems
Nexeon MedSystems Inc, a medical device company, develops, manufactures, and commercializes neurostimulation technology for the treatment of various neurological disorders through electrical stimulation of neural tissues. Its neurostimulation technology platform would provide treatment to patients in several neurostimulator markets, including deep brain stimulation, peripheral electrical nerve stimulation, sacral nerve stimulation, spinal cord stimulation, vagus nerve stimulation, and other neurostimulator markets.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nexeon MedSystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexeon MedSystems and related companies with MarketBeat.com's FREE daily email newsletter.